RxDoctor Payments Data

Senthilrajan Natarajan, MD

Cardiovascular Disease · Rochester, NYNPI 1487655692

Payments from drug & device makers

$33,855in general payments, 2019–2025

Across 247 payments — averaging $137.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kestra Medical Technology Services, Inc.$30K
  • Pfizer$985
  • Biotronik Inc.$779
  • Abbott$599
  • Amgen$500
  • E.r. Squibb & Sons, L.L.C.$351
  • plus $937 from 15 others

What the payments were for

  • Consulting fees$28,40084%
  • Food & beverage$5,43016%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,855 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$379,700
Medicare patients
1,020
Services billed
5,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin868$571,885
EliquisApixaban544$533,119
EntrestoSacubitril/Valsartan415$372,539
XareltoRivaroxaban103$140,499
Repatha SureclickEvolocumab109$126,677
MultaqDronedarone Hcl51$76,477
FarxigaDapagliflozin Propanediol79$64,860
Praluent PenAlirocumab37$27,397
Dofetilide45$19,672
Metoprolol Succinate896$15,420
BrilintaTicagrelor14$13,184
Rosuvastatin Calcium558$11,806
Ezetimibe240$8,867
Dabigatran EtexilateDabigatran Etexilate Mesylate32$8,040
Atorvastatin Calcium543$6,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$65$571,885868 claims
PfizerEliquis$985$533,119544 claims
NovartisEntresto$114$372,539415 claims
Johnson & JohnsonXarelto$30$140,499103 claims
AstraZenecaFarxiga, Brilinta$106$78,04493 claims
Sanofi-aventis U.S. LLCMultaq$118$76,47751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →